SCHEMBL770516

SCHEMBL770516

O=C(CCNS(=O)(=O)Cc1ccccc1)N1CCC2CCCCC2C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44
RAB9A P51151 2/20 0.43
HPGD P15428 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 2/20 0.43
STS P08842 1/20 0.42
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 1/20 0.41
TACR3 P29371 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802379 0.85 HSD17B10 (0.52) LMNARAB9AALDH1A1POLBMAPT
SCHEMBL771597 0.81 ALDH1A1 (0.49) SMN1; SMN2HPGDALDH1A1POLBKMT2A
SCHEMBL770832 0.81 RAB9A (0.49) SMN1; SMN2LMNAMAPK1RAB9AHPGD
SCHEMBL771711 0.78 LMNA (0.49) SMN1; SMN2LMNAHPGDALDH1A1MEN1
SCHEMBL770493 0.78 KDM4E (0.53) SMN1; SMN2ITGB3ITGA2BRAB9AALDH1A1
SCHEMBL7381273 0.78 ALDH1A1 (0.68) LMNARAB9AHPGDALDH1A1POLB
SCHEMBL770735 0.76 TACR3 (0.59) SMN1; SMN2LMNARAB9AALDH1A1POLB
SCHEMBL19390293 0.76 KMT2A (0.51) SMN1; SMN2LMNAMAPK1ITGB3ITGA2B
SCHEMBL769627 0.76 HDAC3 (0.51) SMN1; SMN2HPGDPOLBKMT2A
SCHEMBL769973 0.75 MEN1 (0.53) SMN1; SMN2LMNARAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3653/4885LMNA 3155/4885MAPK1 401/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3637/4885LMNA 3116/4885MAPK1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.